SeqOne Genomics
SeqOne Genomics provides an AI-powered, IVDR-certified NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases. It serves 160+ laboratories across 30+ countries with explainable AI variant interpretation, LIMS-integrated workflow automation, and specialized oncology modules.
- Company typePrivate
- Founded2017
- HeadquartersMontpellier, France
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What SeqOne Genomics does
SeqOne Genomics is a French healthtech company founded in 2017 in Montpellier that operates an AI-powered, cloud-based next-generation sequencing (NGS) bioinformatics platform for clinical genomic analysis. The platform processes raw sequencing data from FASTQ through BAM and VCF to annotated variants, transforming it into actionable clinical insights for molecular laboratories, hospitals, and reference diagnostics providers. The SeqOne Platform is CE-IVD Class C certified under the EU In Vitro Diagnostic Regulation (IVDR) and holds ISO 13485, ISO 27001, ISO 27701, and ISO 42001 certifications, supporting regulated clinical deployment in oncology and rare disease diagnostics across 30+ countries.
The product portfolio centers on the SeqOne Platform, the DiagAI explainable AI variant interpretation engine (transparent 0-100 scoring, validated to recover 98% of causal variants within the top 10 candidates on 565 Genomics England WGS cases), SeqOne Flow for LIMS and IT system automation, and a suite of specialty oncology modules including SomaCGP (comprehensive genomic profiling), SomaLBx (liquid biopsy), SomaMethyl (epigenetic methylation analysis), SomaHemato (IGHV/CLL), and SomaHRD (validated on the PAOLA-1 cohort with 95% concordance to Myriad MyChoice). The April 2025 acquisition of Life & Soft added multi-omics and ISO-certified sequencing services, and the September 2025 acquisition of Congenica contributed the Sapentia clinical decision support platform, bringing the combined entity to 160+ laboratories worldwide. GenomeAlert! provides automated monthly reevaluation of variants against ClinVar updates to maintain diagnostic accuracy over time.
SeqOne generates revenue primarily through a SaaS subscription model layered with pay-per-analysis usage-based pricing, supplemented by professional services for implementation, validation, and clinical interpretation, and channel/licensing arrangements such as the Arquimed partnership for Latin American distribution. The company combines an enterprise field sales motion for strategic hospital and reference lab accounts with a product-led growth motion offering free trial access via regional portals (Europe, US, Australia, Switzerland, UK). The company reports ARR of $9.5 million as of 2025, supports 1,000+ biologists and geneticists, and employs between 101 and 250 staff across offices in Montpellier, Paris, Cambridge (UK, Wellcome Genome Campus), and Wilmington, Delaware.
SeqOne Genomics firmographics
Firmographics- Name
- SeqOne Genomics
- Legal name
- SeqOne S.A.S.
- Website
- https://seqone.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- SeqOne Genomics provides an AI-powered, IVDR-certified NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases. It serves 160+ laboratories across 30+ countries with explainable AI variant interpretation, LIMS-integrated workflow automation, and specialized oncology modules.
- Ownership category
- akta.pro rank
SeqOne Genomics industry classification
Industry- Product category
- Clinical Genomics Bioinformatics Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
Keywords
Where SeqOne Genomics is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
SeqOne Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- SaaS Platform Subscription: Cloud-based genomic analysis platform with pay-per-analysis model. Transparent, flexible pricing with no hidden fees or volume constraints. Subscription-based access with tiered options.
- Usage-based Analysis: Pay-per-analysis pricing model allowing labs to pay based on actual genomic test volume processed.
- Professional Services: Implementation support, training, technical onboarding, and specialized bioinformatics services including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.
- Platform Licensing: Platform licensing to channel partners like Arquimed for deployment to laboratories across regions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Pay-per-analysis with no volume constraints |
| Freemium | Monthly | Free trial access to platform |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
SeqOne Genomics product offering
Product offeringCore offering
SeqOne Genomics provides a cloud-based AI-powered NGS bioinformatics platform that transforms raw next-generation sequencing data (FASTQ → BAM → VCF → annotated VCF) into clinically actionable insights for oncology and rare disease diagnostics. The platform combines the SeqOne Platform with DiagAI explainable variant prioritization, SeqOne Flow workflow automation, and a suite of specialized oncology modules (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) to support molecular labs, hospitals, and clinical genetics centers with CE-IVD Class C certified clinical reporting.
Product overview
SeqOne Genomics offers a unified cloud-based AI-powered clinical genomics platform combining advanced bioinformatics pipelines, explainable AI decision support, and integrated workflow automation. The core SeqOne Platform processes NGS data from raw sequencing files through variant calling, annotation, and clinical interpretation. Key modules include DiagAI for explainable AI-powered variant prioritization with transparent scoring, SeqOne Flow for LIMS and IT system integration, and specialized oncology tools (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) for precision cancer diagnostics. The company expanded its portfolio through the September 2025 acquisition of Congenica, adding their Sapentia clinical decision support platform. All products are CE-IVD Class C certified under IVDR for clinical use in oncology and rare diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- SeqOne Platform Cloud-based AI-powered NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases, offering automated pipelines from FASTQ to annotated variants with CE-IVD Class C certification under IVDR. Wet-lab and sequencer-agnostic, supporting panels, exomes, and genomes across short and long-read sequencing.
- DiagAI Explainable AI-powered variant interpretation system using a transparent DiagAI Score (0-100) for ranking genetic variants' disease-causing potential, combining pathogenicity prediction, phenotype matching, and expert-driven rules. Validated on 565 Genomics England WGS cases with 98% of causal variants within top 10 candidates.
- SeqOne Flow Workflow automation engine that integrates with LIMS and IT systems via HL7/FHIR interfaces, automating data pipelines from file transfer to analysis initiation to eliminate manual work and speed up turnaround times.
- GenomeAlert! Automated variant reevaluation agent that monthly reclassifies genetic variants against ClinVar updates to ensure accurate patient diagnoses and treatment decisions.
- Congenica UK-based genomics analysis and clinical decision support platform acquired by SeqOne in September 2025, providing Sapentia technology and strengthening AI-powered genomic medicine offerings; combined entity serves over 160 laboratories across 30+ countries.
- Clinical Interpretation Services Expert clinical interpretation services supporting molecular labs with genomic analysis, enabling delivery of actionable insights to clinicians and patients, including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.
Quantifiable outcome
- 98% of causal variants identified within top 10 candidates (validated on 565 Genomics England WGS cases)
- +4 more outcomes
Companies that use SeqOne Genomics
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
SeqOne Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature10 records
SeqOne Genomics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- ArquimedcorePartnership to deploy SeqOne's genomic interpretation platform to laboratories across Chile. Arquimed will integrate SeqOne's clinically validated platform into its portfolio of end-to-end healthcare solutions, expanding precision medicine capabilities in Latin America.
- CongenicaflagshipAcquisition of UK-based Congenica to strengthen position in AI-powered genomic medicine. Unified genomic analysis and clinical decision support technology. Combined entity serves 160+ laboratories across 30+ countries.
- AgilentcoreStrategic collaboration to advance liquid biopsy data analysis for oncology applications. Partnership combines Agilent's sequencing capabilities with SeqOne's AI-powered analysis platform for comprehensive liquid biopsy solutions.
- Life & SoftcoreAcquisition of Life & Soft to expand multi-omics capabilities and service offerings with ISO-certified sequencing platform.
- MGI TechcorePartnership to develop end-to-end genomic analysis solutions, combining MGI's sequencing technology with SeqOne's AI-powered platform for integrated workflows.
- Oxford Nanopore TechnologiescorePartnership to support interpretation of Nanopore sequencing in clinical use. Delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
SeqOne Genomics competitors and assessment
Company assessmentDirect peers
- Sophia Genetics: Sophia Genetics offers an AI-powered clinical genomics platform (SOPHiA DDM) that analyzes NGS data for oncology, rare disease, and hereditary cancer customers. It is the closest direct competitor to SeqOne in serving molecular labs with multi-modal genomic interpretation.
- Fabric Genomics (Illumina): Fabric Genomics (acquired by Illumina) provides AI-driven clinical genomic interpretation for rare disease and oncology, including the GEM and OPAL algorithms. It competes head-to-head with SeqOne's DiagAI and rare-disease workflows.
- Velsera (Seven Bridges / Pierian): Velsera, formed from the merger of Seven Bridges and Pierian, operates a clinical genomics analysis and interpretation platform for hospitals, labs, and pharma. It directly competes with SeqOne in tertiary genomic analysis and clinical decision support.
- BC Platforms: BC Platforms provides a genomics data platform combining biobanking, NGS analysis, and clinical interpretation. It targets similar clinical and research lab customers as SeqOne, particularly in Europe.
- Lifebit Biotech: Lifebit operates a federated cloud genomics platform for clinical and research genomics. It competes with SeqOne's cloud-based NGS analysis offering, particularly for translational and population genomics customers.
- DNAnexus: DNAnexus provides a cloud-based genomics data analysis and management platform used by clinical labs, hospitals, and biopharma. It is comparable to SeqOne's cloud NGS analysis infrastructure layer.
Broad incumbents
- QIAGEN Digital Insights: QIAGEN's Digital Insights business (including QCI Interpret and Ingenuity) provides clinical variant interpretation and bioinformatics tools as part of a broader sample-to-insight portfolio, directly competing with SeqOne while also leveraging QIAGEN's installed wet-lab base.
- Illumina (DRAGEN / Emedgene): Illumina bundles DRAGEN secondary analysis and Emedgene clinical interpretation with its dominant sequencer footprint, making it a broad incumbent competitor to SeqOne in clinical genomics analysis.
- Tempus: Tempus combines molecular profiling, AI-driven analytics, and clinical decision support for oncology and rare disease. While broader than SeqOne (including its own lab), it overlaps in NGS interpretation and precision oncology.
Emerging players
- Personalis: Personalis offers a comprehensive genomic profiling platform (NeXT Personal) for oncology customers with its own lab plus analytics. It overlaps with SeqOne's oncology/SomaCGP and SomaLBx positioning in tumor profiling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SeqOne Genomics social profiles
Digital presenceSeqOne Genomics compliance and trust
Trust signalCompliance12 records
SeqOne Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SeqOne Genomics leadership team
Management profileNumber of profiles
Profiles4 records
SeqOne Genomics subsidiaries and ownership
Company hierarchySubsidiaries2 records
SeqOne Genomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SeqOne Genomics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SeqOne Genomics
What does SeqOne Genomics do?
SeqOne Genomics provides a cloud-based AI-powered NGS bioinformatics platform that transforms raw next-generation sequencing data (FASTQ → BAM → VCF → annotated VCF) into clinically actionable insights for oncology and rare disease diagnostics. The platform combines the SeqOne Platform with DiagAI explainable variant prioritization, SeqOne Flow workflow automation, and a suite of specialized oncology modules (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) to support molecular labs, hospitals, and clinical genetics centers with CE-IVD Class C certified clinical reporting.
Is SeqOne Genomics a public or private company?
SeqOne Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was SeqOne Genomics founded?
SeqOne Genomics was founded in 2017. It employs 101 to 250 people.
Where is SeqOne Genomics based?
SeqOne Genomics is headquartered in Montpellier, France, in the Europe region.
How does SeqOne Genomics make money?
Four revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are usage-based Analysis, professional Services and platform Licensing.
Who are SeqOne Genomics's main competitors?
Direct peers on record are Sophia Genetics, Fabric Genomics (Illumina), Velsera (Seven Bridges / Pierian), BC Platforms, Lifebit Biotech and DNAnexus. Broad incumbents are QIAGEN Digital Insights, Illumina (DRAGEN / Emedgene) and Tempus. Personalis is listed as an emerging player.
Does SeqOne Genomics have an API?
Yes. SeqOne offers a public API enabling customer IT teams to integrate autonomously. The API supports analysis triggering, file upload/download, and is designed as a product with comprehensive documentation, SDKs, and sandbox environments. The platform also supports SeqOne Flow Premium for workflow automation including LIMS connectors and HL7/FHIR interfaces. Developer documentation is at Not specified.
What industry is SeqOne Genomics in?
SeqOne Genomics's product category is Clinical Genomics Bioinformatics Software. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 518210 and its SIC code is 7370.